The MAGE-A4 expression rate was high in oesophageal cancer (54.9%), head and neck cancer (37.5%), gastric cancer (35.0%) and ovarian cancer (34.2%) (Table 2). Here, MAGEA4 is linked to carcinoma of esophagus.